Gain Therapeutics, Inc. - COM (GANX)

Historical Holders from Q1 2021 to Q3 2025

Symbol
GANX on Nasdaq
Type / Class
Equity / COM
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
4,341,662
Holdings value
$7,702,477
% of all portfolios
0%
Number of holders
38
Number of buys
23
Number of sells
-9
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Institutional Holders of Gain Therapeutics, Inc. - COM (GANX)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 4,341,662 $7,702,477 +$1,416,796 $1.77 38
2025 Q2 3,541,963 $6,489,816 +$1,630,735 $1.8 34
2025 Q1 2,656,706 $5,066,902 +$1,576,755 $1.91 32
2024 Q4 1,825,471 $3,943,571 +$1,072,822 $2.16 24
2024 Q3 1,340,581 $2,396,972 -$2,122,564 $1.78 19
2024 Q2 3,036,722 $3,885,911 +$107,658 $1.28 27
2024 Q1 1,867,615 $7,040,313 +$1,135,475 $3.77 26
2023 Q4 1,344,999 $4,391,761 +$109,510 $3.26 23
2023 Q3 1,515,523 $4,954,628 +$796,941 $3.28 24
2023 Q2 1,267,676 $5,679,140 +$520,599 $4.48 24
2023 Q1 1,149,488 $5,544,695 +$288,585 $4.82 22
2022 Q4 1,206,763 $3,776,759 -$19,289 $3.13 21
2022 Q3 1,211,675 $3,948,923 +$448,806 $3.26 20
2022 Q2 1,074,231 $3,866,000 -$335,927 $3.6 15
2022 Q1 1,161,662 $4,748,000 +$362,441 $4.09 16
2021 Q4 1,054,535 $5,700,000 +$811,336 $5.38 17
2021 Q3 892,606 $6,646,000 -$472,237 $7.45 13
2021 Q2 894,199 $8,945,000 -$1,891,617 $10 12
2021 Q1 1,006,151 $15,020,000 +$15,020,002 $14.92 12